Cytoprotective effects of eupatilin, a novel antioxidative flavone, in oxidative stress-induced gastric mucosal cell damage

Oh TaeYoung, Kim JuMi[o], Ahn ByoungOk, Kim WonBae, Park EunJoo, Kim YongSeok, Lee ZeeWon, Ha KwonSoo

Dong-A Pharmaceutical Research Institute;College of Medicine, Hanyang University;College of Medicine, Kangwon University

Background: Alcohol, *Helicobacter pylori*, stress and NSAIDs-activated neutrophils all produce reactive oxygen species (ROS), which play an important role in gastric mucosal damage. Eupatilin is an active component of *Artemisia asiatica* possessing cytoprotective effect. The effect of eupatilin on the production of ROS and cellular damage in AGS and ECV304 cells were evaluated to prove the cytoprotective action against the above mentioned gastric mucosal cell damages. Methods: In this study cell damages were induced by the treatment of H_2O_2 *in vitro*. The changes of ROS including superoxide anion, hydroxyl radical and hydrogen peroxide was measured in the presence of eupatilin. Release of lactate dehydrogenase (LDH) was investigated for an index of cellular damage. Results: Eupatilin (150 mM) reduced LDH leakage in AGS cell, and significantly inhibited ROS production in ECV304 cells in a dose-dependent manner. A 200 mM concentration of eupatilin inhibited ROS production by 94.7%. The activity of glutathione peroxidase was significantly increased 6 times of control levels after the treatment of eupatilin (150 mM). Confocal microscopy revealed that eupatilin directly decreases ROS production in ECV304 cells that exposed to 5 mM H2DCFDA and 200 mM arachidonic acid and prevented the influx of calcium within cells, signifying the definite role of eupatilin on the cytoprotective actions in gastric mucosal cell damages. Conclusions: Eupatilin exerts cytoprotective effect through reduction of ROS generation and the activation of antioxidative system.

[PA1-9] [04/17/2003 (Thr) 14:00 - 17:00 / Hall P]

DA 11004, a synthetic IDPc inhibitor, inhibits the high fat high sucrose diet-induced obesity in C57BL/6 mice.

Jeong MiYoung, Shin ChangYell, Sohn JinBup, Lee InKi, Son Miwon, Bae CheolJun, Byun JongSoo, Kim DongSung, Kim SoonHae, Yoo Moohi, Huh TaeLin*, Kim WonBae

Research Laboratories, Dong-A Pharm. Co. Ltd.47-5, Sanggal, Kiheung, Yongin, Kyunggi 449-900, Korea. *Department of Genetic Engineering, College of Natural Sciences, Kyung Pook National University

Recently, it has been known that NADPH-dependent isocitrate dehydrogenase (IDPc) involves in the obesity through production of NADPH, an important cofactor. DA-11004 is a synthetic potent IDPc inhibitor that IC_{50} for IDPc is 1.49μM (0.9μg/ml). The purpose of this study was to evaluate the effects of DA-11004 on the high fat high sucrose (HF)-induced obesity in C57BL/6 mice. After completing an 8-week period of experiment, mice were sacrificed at 1hr after the last DA-11004 treatment and their blood, liver, and adipose tissues (epididymal and retroperitoneal fat) were collected. There is a significant difference in the pattern of increases of body weight between HF control and DA-11004 group. In the DA-11004 (100mg/kg) treated groups, the increases of body weight and diet consumption were significantly declined and a content of epididymal fat and retroperitoneal fat was also significantly decreased as compared with HF control. DA-11004 (100mg/kg) inhibited the IDPc activity and NADPH levels in plasma, but not in liver or epididymal fat. We examined the levels of DA-11004 in plasma, liver, and epididymal fat. In plasma, levels of DA-11004 (30mg/kg) or (100mg/kg) was 0.760 ± 0.14, 3.340 ± 0.40 (μg/ml), respectively. The levels of free fatty acid (FFA) or glucose in plasma were decreased as compared with HF control.
In conclusion, DA-11004 inhibited the fatty acid synthesis in adipose tissues via IDPc inhibition

and decreased the plasma glucose levels and FFA in HF diet-induced obesity of C57BL/6 mice.

[PA1-10] [04/17/2003 (Thr) 14:00 - 17:00 / Hall P]

Metabolism of YH3945, a novel anticancer drug, in rats using 14C-labeled compound

Lee Jaeick[o], Son Junghyun, Ahn Byung-Nak, Lee Bongyong, Kim Dong-Hyun Kim

Korea Institute of Science and Technology, Yuhan Research Institute

The metabolism of a novel anticancer agent 1-{3-[3-(4-Cyano -benzyl)-3H-imidazol-4-yl]-propyl}-3-(6-methoxy-pyridin-3-yl)-1-(2-trifluoromethyl-benzyl)-thiourea (YH3945) were investigated in the Sprague-Dawley rat after single oral and i.v. administration of [14C]-YH3945. Bile, feces, urine and plasma were collected and analyzed by an HPLC system equipped with multiple detectors. The present analysis system includes the simultaneous detection technique of three different detectors (diod array detector-radioactivity flow detector-tandem mass spectrometry) in single run. The structures of each metabolite were characterized based on UV, tandem mass (MS2 and MS3) and NMR (1H and TOCSY) spectral analyses. YH3945 was metabolized to seventeen different metabolites including glucuronide conjugate. The four major metabolic pathways of YH3945 in rat were identified as O-demethylation of pyridine moiety, N-debenzylation of imidazol moiety, hydroxylation of aromatic ring and recyclization between pyridine and benzylic carbon. Especially, nonenzymatic reaction mechanism of metabolite generated by the recyclization was theoretically postulated.

[PA1-11] [04/17/2003 (Thr) 14:00 - 17:00 / Hall P]

Attenuation of nicotine-induced locomotor sensitization in μ-opioid receptor knockout mice

Yoo JiHoon[o], Yang EunMi, Kim KyungIn, Lee SeokYong, Jang ChoonGon

Department of Pharmacology, College of Pharmacy, Sungkyunkwan University, Suwon, Korea

The present study was undertaken to examine the hypothesis that μ-opioid receptors play a crucial role in behavioral sensitization to nicotine using μ-opioid receptor knockout mice.
All mice were treated acutely or repeatedly with nicotine 0.05 mg/kg twice daily for 7 consecutive days. The mice were challenged with nicotine on day 11. And locomotor activity was measured for 30min. Locomotor activity challenged by acute nicotine was no difference between μ-opioid receptor knockout and wild-type mice. Repeated treatment with nicotine induced behavioral sensitization in wild-type mice on days 7 and 11. In contrast, nicotine exposure failed to develop behavioral sensitization in μ-opioid knockout mice. This behavioral sensitization was accompanied by an incerese in D(2) receptor binding in striatum of the μ-opioid knockout mice compared with the wild-type mice on day 7. However, D(1) receptor expression was not changed in the striatum and nucleus accumbens.
These results suggest that abolishment of nicotine-induced behavioral sensitization in the μ-opioid receptor knockout mice may be related to the increase of D(2) receptor binding in the striatum.

[PA1-12] [04/17/2003 (Thr) 14:00 - 17:00 / Hall P]